NCT07807683Completed
Circulating Endothelial Cells (CECs) as Potential Predictive/Prognostic Biomarkers in Ovarian Cancer
Flow Cytometric Evaluation of the Role of Circulating Endothelial Cells (CECs) as Potential Predictive/Prognostic Biomarkers in Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
Anti-angiogenic agents, such as Bevacizumab, have demonstrated survival benefits in ovarian cancer, particularly in patients at high risk of disease progression. However, these therapies are costly, associated with potential side effects, and may negatively impact quality of life, benefiting only specific patient subgroups. Therefore, identifying reliable, predictive, and prognostic biomarkers that can be seamlessly integrated into clinical practice is essential to optimize patient selection. Circulating endothelial cells (CECs)-mature endothelial cells shed from vascular walls following blood vessel damage-represent a promising biomarker for monitoring vascular injury, treatment response, and disease recurrence. While flow cytometry offers a rapid, cost-effective, and standardized approach for CEC enumeration, methodological variability across laboratories has historically limited its clinical utility. To overcome this, this study utilizes a standardized flow cytometry protocol (developed by Beckton Dickinson and the SCENIC consortium) combining DNA staining with a dried, pre-titrated 5-antibody panel to ensure consistent and reproducible CEC quantification. Additionally, emerging evidence suggests that specific microRNA (miRNA) expression profiles in primary tumor tissue and plasma reflect vascular damage and response to anti-angiogenic therapy. This study aims to evaluate the predictive and prognostic role of CEC counts (at baseline and post-treatment) in ovarian cancer patients receiving standard chemotherapy with or without Bevacizumab. Furthermore, it seeks to explore the correlation between baseline CEC levels and the expression of selected miRNAs in plasma and primary tumors.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 148 (actual)
- First submitted
- 31 Aug 2026
- Start date
- Jan 2014
- Primary completion date
- Dec 2018
- Lead sponsor
- Centro di Riferimento Oncologico - Aviano
- Diseases
- Ovarian cancer
- NCT number
- NCT07807683
What you commit to
- Study type: Observational
- Participants enrolled: 148
- From Jan 2014 to the primary completion date, Dec 2018
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pharmacological treatment completed less than 48 hours prior
- End of menstrual cycle less than 15 days prior
Other illness
- Diabetes
- Hypertension
- Active infectious states or chronic inflammatory diseases
- Active or previous malignancies
- Cardiovascular disease / Heart disease
- Active gastric or duodenal ulcer
- Positive serology for HIV, Hepatitis A, B, or C infection
Other
- Statin treatment
- Endometriosis
- Non-fasting subjects
- Obesity
- Hypercholesterolemia
Who the study is looking for
- Healthy adults caucasian female
- Non-smoker
- Normal blood pressure values
- Normal complete blood count (CBC)
- Normal blood chemistry values
- Caucasian
- Patients with confirmed histological diagnosis of ovarian carcinoma (all histotypes)
- Treatment-naive or with disease recurrence occurring more than 12 months after the start of therapy
- Normal systolic and diastolic blood pressure values, no cardiovascular comorbidities
- Written informed consent
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.